US · ACRV · BIOTECHNOLOGY
Acrivon Therapeutics, Inc. Common Stock (ACRV) intrinsic value and stock valuation
$1.15as of 2026-11-21 · Mkt cap 70.19M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Acrivon Therapeutics, Inc. Common Stock DCF and intrinsic value
InvestorsCraft values ACRV with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ACRV’s statements →
Acrivon Therapeutics, Inc. Common Stock Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2020–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-84.11M | -$-89.2M | -$-67.24M | -$-32.66M | -$-16.18M |
| Net income | -$-77.91M | -$-80.56M | -$-60.39M | -$-31.17M | -$-16.24M |
| EPSd | -$-2.02M | -$-2.1M | -$-2.74M | -$-1.42M | -$-1.26M |
| Operating cash flow | -$-63.66M | -$-65.67M | -$-42.64M | -$-30.12M | -$-13.98M |
| Capital expenditure | -$-1.67M | -$-2.77M | -$-1.29M | -$-2.17M | -$-240K |
| Free cash flow | -$-65.33M | -$-68.44M | -$-43.93M | -$-32.28M | -$-14.22M |
| Total assets | $129.7M | $196.6M | $138.3M | $181.2M | $106.6M |
| Total debt | $2.71M | $3.65M | $4.64M | $4.96M | $5.63M |
| Net debt | -$-38.79M | -$-36.17M | -$-31.37M | -$-24.56M | -$-93.97M |
| Total equity | $112.5M | $176.8M | $121.2M | $170.5M | -$-23.81M |
| Cash and short-term investments | $118.6M | $179.5M | $127.5M | $127.8M | $99.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $1.36M | $1.01M | $540K | $0.00 | $0.00 |
| Gross profit | -$-1.36M | -$-1.01M | -$-540K | $0.00 | $0.00 |
| Research and development expenses | $60M | $64M | $45.5M | $24M | $13.7M |
| Selling, general and administrative expenses | $24.1M | $25.2M | $21.2M | $8.71M | $2.47M |
| Other expenses | -$-1.36M | -$-1.01M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $82.8M | $88.2M | $66.7M | $32.7M | $16.2M |
| Cost and expenses | $84.1M | $89.2M | $67.2M | $32.7M | $16.2M |
| Interest income | $6.48M | $9.2M | $7.04M | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $1.36M | $1.01M | $540K | $360K | $40K |
| Ebitda | -$-76.55M | -$-79.55M | -$-59.85M | -$-30.8M | -$-16.21M |
| Operating income | -$-84.11M | -$-89.2M | -$-67.24M | -$-32.66M | -$-16.18M |
| Total other income/expenses, net | $6.21M | $8.64M | $6.85M | $1.49M | -$-60K |
| Income before tax | -$-77.91M | -$-80.56M | -$-60.39M | -$-31.17M | -$-16.24M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-77.91M | -$-80.56M | -$-60.39M | -$-31.17M | -$-16.24M |
| Weighted average shares outstanding | $38.5M | $38.3M | $22.1M | $21.9M | $12.9M |
| Weighted average diluted shares outstanding | $38.5M | $38.3M | $22.1M | $21.9M | $12.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $118.6M | $179.5M | $127.5M | $127.8M | $99.6M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $120.4M | $181.6M | $129.7M | $132.1M | $100.4M |
| Property, plant and equipment, net | $7.42M | $8.03M | $7.91M | $6.86M | $5.79M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $5.09M | $0.00 | $41.9M | $0.00 |
| Total non-current assets | $9.27M | $15M | $8.57M | $49.1M | $6.18M |
| Total assets | $129.7M | $196.6M | $138.3M | $181.2M | $106.6M |
| Accounts payable | $2.28M | $760K | $5.05M | $900K | $960K |
| Short-term debt | $1.17M | $1.06M | $880K | $730K | $660K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $70K | $70K |
| Total current liabilities | $15.7M | $17.2M | $13.3M | $6.52M | $2.91M |
| Long-term debt | $1.54M | $2.59M | $3.77M | $4.24M | $4.96M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $1.54M | $2.59M | $3.77M | $4.24M | $127.5M |
| Capital lease obligations | $2.71M | $2.59M | $4.64M | $4.96M | $5.63M |
| Total liabilities | $17.2M | $19.8M | $17.1M | $10.8M | $130.4M |
| Common stock | $30K | $30K | $20K | $20K | $0.00 |
| Retained earnings | -$-274.88M | -$-196.98M | -$-116.42M | -$-56.03M | -$-24.86M |
| Accumulated other comprehensive income (loss) | $110K | $450K | -$-80K | -$-100K | $0.00 |
| Total equity | $112.5M | $176.8M | $121.2M | $170.5M | -$-23.81M |
| Total investments | $77.1M | $144.8M | $91.4M | $140.1M | $0.00 |
| Total debt | $2.71M | $3.65M | $4.64M | $4.96M | $5.63M |
| Net debt | -$-38.79M | -$-36.17M | -$-31.37M | -$-24.56M | -$-93.97M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-77.91M | -$-80.56M | -$-60.39M | -$-31.17M | -$-16.24M |
| Depreciation and amortization | $920K | $1.01M | $540K | $360K | $40K |
| Stock-based compensation | $14.7M | $14.3M | $11.6M | $2.19M | $500K |
| Change in working capital | -$-2.43M | $2.44M | $8.14M | -$-1.53M | $330K |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $1.54M | -$-3.59M | $3.61M | -$-240K | $800K |
| Net cash provided by operating activities | -$-63.66M | -$-65.67M | -$-42.64M | -$-30.12M | -$-13.98M |
| Investments in property, plant and equipment | -$-1.67M | -$-2.77M | -$-1.29M | -$-2.17M | -$-240K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $66.1M | -$-51.77M | $50.7M | -$-141.68M | -$-240K |
| Common stock issued | $0.00 | $70M | -$-260K | $104.5M | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-750K | $121M | -$-1.55M | $101.7M | $112.2M |
| Net change in cash | $1.69M | $3.59M | $6.52M | -$-70.08M | $98M |
| Cash at end of period | $41.7M | $40M | $36.4M | $29.9M | $100M |
| Operating cash flow | -$-63.66M | -$-65.67M | -$-42.64M | -$-30.12M | -$-13.98M |
| Capital expenditure | -$-1.67M | -$-2.77M | -$-1.29M | -$-2.17M | -$-240K |
| Free cash flow | -$-65.33M | -$-68.44M | -$-43.93M | -$-32.28M | -$-14.22M |
Line items
Line items
Line items
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
- CEO
- Peter Blume-Jensen
- Employees
- 76
- Beta
- 1.83
Explore
Frequently asked questions
What is the intrinsic value of Acrivon Therapeutics, Inc. Common Stock (ACRV)?
InvestorsCraft does not currently publish an intrinsic value for ACRV. How the IC value is calculated.
Is ACRV undervalued?
InvestorsCraft does not publish an undervaluation signal for ACRV at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.